Joe Biden Continues Treatment for Stage 4 Prostate Cancer
The 83-year-old is undergoing chemotherapy for metastatic cancer, illustrating the long-term nature of advanced care.
Updated on Oct. 21, 2026 in Cancer
Joe Biden, 83, continues his journey with stage 4 prostate cancer following a diagnosis in May 2025. He began chemotherapy in the fall of 2025 for the advanced disease, which includes bone metastasis.
Why it matters
Understanding advanced prostate cancer requires navigating complex diagnostic factors like the Gleason score, which helps clinicians determine how aggressively the cancer may behave. Managing stage 4 disease, particularly with bone metastasis, typically involves long-term, multi-modal treatment strategies.
A diagnostic assessment confirmed stage 4 prostate cancer with bone metastasis, characterized by a high-grade Gleason score of 9. The current treatment plan involves ongoing chemotherapy, which was initiated in the fall of 2025.
The players
Joe Biden
An 83-year-old currently undergoing treatment for metastatic prostate cancer.
The details
Prostate cancer is categorized by a Gleason score, a grading system that evaluates how closely the cancer cells resemble normal tissue under a microscope. A score of 9 indicates a high-grade, aggressive tumor, and the progression to stage 4 signifies the cancer has spread beyond the prostate to other parts of the body, such as the bone. Chemotherapy is commonly used in these advanced stages to slow the growth of cancer cells that have become resistant to hormone-based treatments.
Timeline
May 2025: Diagnosis of stage 4 prostate cancer.
Fall 2025: Initiation of chemotherapy treatment.
Health Landscape
The clinical approach to stage 4 prostate cancer has evolved from purely palliative care to increasingly sophisticated systemic therapies aimed at extending survival. This case reflects the standard management of metastatic disease, which requires ongoing monitoring and intervention to manage long-term progression.
For individuals managing prostate health, symptoms such as urinary changes should always be discussed with a physician, as early detection remains vital. Understanding the staging and Gleason scoring system can help patients engage in more informed conversations with their oncology care teams.
The takeaway
Advanced prostate cancer management focuses on balancing treatment efficacy with quality of life through long-term care plans. Patients should discuss their specific pathology reports and diagnostic scores with their medical team to better understand their individual prognosis and treatment options.
Further reading
For more information on the complexities of prostate cancer diagnostics, visit Cancer.
